Comparative Pharmacology
Head-to-head clinical analysis: IFEX versus URACIL MUSTARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IFEX versus URACIL MUSTARD.
IFEX vs URACIL MUSTARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IFEX (ifosfamide) is an alkylating agent that crosslinks DNA strands, inhibiting DNA synthesis and transcription. It requires hepatic activation via CYP3A4 to form active metabolites (ifosfamide mustard and acrolein).
Uracil mustard is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
1.2 g/m2 intravenously daily for 5 consecutive days every 3 weeks, or 5 g/m2 as a 24-hour continuous infusion every 3 weeks.
1 mg orally daily for 3 weeks, then 1 mg daily every 4 weeks, or 0.15 mg/kg orally once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours in adults with normal renal function; prolonged in renal impairment.
Clinical Note
moderateUracil mustard + Digoxin
"Uracil mustard may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateUracil mustard + Digitoxin
"Uracil mustard may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateUracil mustard + Deslanoside
"Uracil mustard may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateUracil mustard + Acetyldigitoxin
"Uracil mustard may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 6–8 hours in patients with normal renal function; may be prolonged with renal impairment
Renal: approximately 50-70% of the administered dose is excreted in urine as unchanged drug; biliary/fecal excretion is minimal, accounting for less than 5%.
Primarily renal (56-80% as unchanged drug and metabolites); minor fecal (10%)
Category C
Category C
Alkylating Agent
Alkylating Agent